Response
Dr Szczeklik and colleagues suggest differences in statin use or distribution of the platelet Pl A2 polymorphism between cases and controls as possible explanations for our findings 1 of an association between aspirin-resistant thromboxane biosynthesis and risk of myocardial infarction, stroke, or cardiovascular death. However, we could not demonstrate an association between lipid-lowering therapy and urinary thromboxane B 2 concentrations, and our results remained unchanged even after adjusting for differences between cases and controls in the use of lipid-lowering therapy. Meanwhile, reports of an association between the Pl A2 polymorphism and atherosclerotic vascular disease have been conflicting, 2 and we remain unaware of any convincing data demonstrating a significant clinical interaction between statin use or the Pl A2 polymorphism and aspirin therapy.
Great interest remains in the possible role of platelet membrane glycoprotein or other (eg, COX-1) gene polymorphisms in determining an individual's response to antiplatelet therapy. 3 However, recent studies that have examined this question with respect to Pl A2 polymorphism and aspirin included only small numbers of healthy subjects, used nonspecific laboratory measures such as the bleeding time, platelet aggregation studies, or blood markers of thrombin generation to measure the inhibitory effect of aspirin, and did not correlate their findings with clinical outcomes. 4 -6 Future studies will require large sample sizes with sufficient numbers of clinical outcome events to reliably determine a possible interaction between the Pl A2 polymorphism and aspirin.
